Company intelligence / Profile preview
Actio Biosciences
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
Overview
The company is developing a TRPV4 program for CMT2C and other bone diseases, along with two additional programs for genetic epilepsies and genetic skin conditions. No specific clinical results mentioned yet.
- Therapeutic areas
- DermatologyRheumatologyRare DiseasesNeurology
- Modalities
- therapeutics
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Actio Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Actio Biosciences.